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Hsp90 inhibitorThe activator of Hsp90 ATPase, Aha1, is an Hsp90 co-chaperone that has been suggested to act as a general
stimulator of Hsp90 function. In this report, we have characterized the interaction of Aha1 with Hsp90 and its
co-chaperones in rabbit reticulocyte lysate (RRL) and in HeLa cell extracts. Complexes formed by Aha1 with
Hsp90 in RRL were stabilized by molybdate and contained the co-chaperones FKBP52 and p23/Sba1, but
lacked HOP/Sti1 and Cdc37. Aha1 complexes isolated from HeLa cell extracts also contained Hsp70 and
DNAJA1. Over-expression of Aha1 has been reported to stimulate the activity of v-Src and steroid hormone
receptors ectopically expressed in yeast, however, no interaction between Aha1 and nascent v-Src or the
progesterone receptor could be detected in RRL. Contrary to expectations, over-expression of Aha1 also
inhibited the rate of Hsp90-dependent refolding of denatured luciferase. A number of potential client
proteins that speciﬁcally associated with Aha1 were identiﬁed by liquid chromatography/ tandem mass
spectrometry (LC–MS/MS) and veriﬁed by Western blotting. The proteins identiﬁed suggest that Aha1 may
play roles in modulating RNA splicing and DNA repair, in addition to other cellular processes.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Hsp90 is a molecular chaperone that is required for the proper
function of numerous proteins in eukaryotic cells (reviewed in [1–3]).
Hsp90 functions in conjunction with a number of partner proteins
commonly referred to as co-chaperones [1–3]. The Hsp90 co-
chaperone Aha1 was so named because it was found to be an
activator of Hsp90's ATPase activity [4,5]. Hsp90 and Aha1 interact
physically [4–8], with Aha1's N-terminal domain binding primarily to
Hsp90's middle and its C-terminal domain interacting with Hsp90's
N-terminal domain [4,7,9,10]. High afﬁnity binding and potent
stimulation of Hsp90's ATPase activity have been found to require
both of Aha1's domains [4,5].
While Aha1 and its homolog Hch1p are not required for viability
in yeast, studies have demonstrated that the genes become crucial for
cell viability under non-optimal growth conditions when Hsp90
levels are limiting [4,5,11]. In addition, in yeast strains where Hsp90
activity was limiting, over-expression of Hch1p enhanced the
maturation of a heterologous Hsp90 target protein, v-Src [11], while
deletion of the genes coding for Hch1p and Aha1 markedly decreased
the activity of ectopically expressed v-Src [4,5]. Furthermore, studiesf Biochemistry and Molecular
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ectopically expressed steroid hormone receptors (SHR) in yeast [12].
These ﬁndings, together with the observation that Aha1 expression is
stress-inducible have led to the current hypothesis that Aha1 is a co-
chaperone that generally enhances Hsp90 function through its ability
to stimulate Hsp90's ATPase activity [5].
Implicit in this hypothesis is the posit that Aha1 is a general co-
chaperone for Hsp90-dependent clients. However, to date there are
only a limited number of reports documenting complexes of Hsp90
and Aha1 containing bound client, or the effect of Aha1 on client
protein activity. Aha1 was originally described as a 38-kDa protein
(p38) that interacted with VSV-G and was postulated to associate
transiently with endoplasmic reticulum (ER) membranes, possibly
modulating the transit of VSV-G and other cargo proteins from the ER
to the Golgi [13]. Consistent with this notion, Aha1 [9,14,15] and
Hsp90 [16,17] have been shown to interact with the cystic ﬁbrosis
transmembrane conductance regulator (CFTR) and its folding mutant
CFTR(ΔF508), in addition to wild-type and mutant melanocortin-4
receptors (MC4R, [18]), and modulate their transport to the plasma
membrane. Mutations that impair Aha1 function [9], down regulation
of Aha1 expression [15], or displacement of Aha1 from CFTR(ΔF508)
[14] rescue misfolding of CFTR(ΔF508) and stimulate its maturation
and transport to the plasma membrane. Aha1 also interacts with
Hsp90 complexes containing bound adenine nucleotide transporter
(ANT1), a mitochondrial pre-protein that is targeted by cytoplasmic
chaperone transport complexes to the outer mitochondrial mem-
brane [19]. In addition, Aha1 has been reported to interact with the
SR-protein speciﬁc kinase (SRPK1, [20]), C-RAF and Akt [21], and GTP
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negative regulator of MAL-activator activity in yeast [23].
Herein, the interaction of Aha1 with Hsp90 and its co-chaperones
was characterized in rabbit reticulocyte lysate (RRL) and HeLa cell
extracts, as a number of ambiguous observations have been
previously reported in the literature [5,8,12]. Furthermore, we have
tested the hypothesis that the Aha1-induced increase in v-Src
[4,5,11,12], Akt [21] and SHR activity [12] that has been previously
reported, was due to a direct interaction of Aha1 with the Hsp90-
complexes containing bound nascent client. We report that Aha1
could not be detected in complexes formed between Hsp90 and
nascent v-Src, Akt or the progesterone receptor (PR), even when the
binding of Hsp90 to v-Src, Akt or PR was stabilized by the addition of
molybdate: a condition that also stabilizes the binding of Aha1 to
Hsp90. Furthermore, over-expression of Aha1 did not enhance v-Src
activity, increase phosphotyrosine levels in HeLa cells or stimulate the
rate of Hsp90-dependent refolding of denatured luciferase in RRL
[24]. In addition, a number of potential client proteins that were co-
adsorbed with Aha1 from HeLa cell extracts were identiﬁed by LC–
MS/MS and veriﬁed by Western blotting.
2. Materials and methods
2.1. Analysis of the interactions of Aha1 with Hsp90, co-chaperones and
potential client targets
His-tagged Aha1 was synthesized and radiolabeled via coupled
transcription/translation (TnT) in RRL for 40 min at 30 °C as
previously described [25,26]. His-tagged Aha1 was directly immu-
noabsorbed with anti-IgG-agarose containing bound anti-(His5)
antibody (Qiagen) [25,26]. Hsp90 (OSU anti-Hsp90, [27]), Hsp70
(BB70 monoclonal, [28]), Cdc37 (anti-Cdc37 polyclonal, [29]), p23
(JJ5 monoclonal, [30]), FKBP52 (EC1 monoclonal, [31]), Hip (2G6
monoclonal, [32]) or Hop (F5 monoclonal, [28]) were adsorbed with
polyclonal or monoclonal antibodies directed against each of the
proteins. Immunoprecipitates were washed once with 10 mM PIPES
(pH 7.2), 100 mM NaCl and 0.5% Tween-20 [e.g., 10 mM PIPES buffer
(pH 7.2) containing 100 mMNaCl and 0.5% Tween-20=P100T] and 3
times with P50T and co-adsorbing proteins were analyzed by SDS-
PAGE and Western blotting as previously described [25,26].
v-Src or PR was synthesized by TnT in RRL in the presence or
absence of 15 μg/ml geldanamycin (GA) at 30 °C for 30 min [25,26].
To examine kinase-binding or steroid hormone receptor binding
activity of Aha1, RRL containing radiolabeled v-Src or progesterone
receptor (PR) was mixed with RRL containing [35S]Aha1, synthesized
as described above, followed by an additional 30 min incubation at
30 °C. His-tagged Aha1 or Hsp90 was adsorbed with anti-His-tag or
anti-Hsp90 antibody in the presence or absence of 20 mMmolybdate.
Unless otherwise indicated in the ﬁgure legends, immunoresins were
washed 4 times with P50T in the presence or absence of 20 mM
molybdate as indicated in the legends of the ﬁgures. To assess the
interaction of endogenous Aha1 with Akt, Flag-tagged Akt was
generated by TnT and immunoadsorbed with anti-Flag antibody as
described above. Samples were analyzed by SDS-PAGE, Western
blotting and/or autoradiography.
2.2. In vitro v-Src protein kinase assay
[35S]-Labeled v-Src was synthesized by TnT in RRL in the presence
or absence of 15 μg/ml GA for 30 min at 30 °C. The lysate was then
mixed with TnT lysate containing newly synthesized [35S]-labeled
Aha1 or mock lysate followed by another 30 min incubation at 30 °C.
The mixtures were immunoprecipitated with anti-Src monoclonal
antibody for 1 h at 4 °C with gentle rocking. The immunoresins were
then washed twice with ice-cold P500T and twice with P150. Similar
results were obtained when immunoresins were washed twice withP300 and twice with P100. The v-Src kinase assay was carried out
by incubating the immunoresins with 0.5 μg/ml acid-treated enolase
and 1.0 mM ATP in kinase buffer containing 10 mM PIPES pH 7.4,
150 mM NaCl, and 20 mM MnCl2 for 5 min at 37 °C. Boiling SDS
sample buffer was then added into the assay mixtures to end the
reaction, and samples were analyzed by SDS-PAGE on an 8% gel and
then transferred to PVDF membrane. The newly synthesized v-Src
and His6-Aha1 were detected by autoradiography. The co-adsorbed
Hsp90 and phosphotyrosine were detected by Western blotting with
anti-Hsp90 antibody [27] and anti-phospho-tyrosine monoclonal
antibody (P-Tyo-100, Cell Signaling, Cat #9411), respectively. The
endogenous and His-tagged Aha1 in the input was detected by
Western blotting with rabbit polyclonal anti-Aha1 [13].
2.3. Akt kinase assay
Human Aha1 sequence was cloned into pcDNA3.1 vector with an
upstream Flag-epitope tag. Plasmid encoding Flag-Aha1was trans-
fected into HeLa cells cultured on a 6-well plate for 48 h. Cells were
washed once with 20 mM sodium phosphate buffer (pH 7.4)
containing 150 mM NaCl (phosphate buffered saline, PBS) and then
incubated with ice-cold 1× cell lysis buffer (Akt Kinase Assay Kit, Cell
Signaling, catalog #9840) for 5 min. Cells were scraped off the plate
and sonicated on ice. Cell lysates were centrifuged at 14,000 rpm for
10 min at 4 °C. The supernatants were incubated with immobilized
phospho-Akt (Ser473) rabbit antibody beads with gentle rocking for
4 h at 4 °C followed by washing with 1× cell lysis buffer and then 1×
kinase buffer. Immuno-beads were suspended in 1× kinase buffer
with 0.2 mM ATP and 0.2 μg GSK-3 fusion protein and then incubated
for 30 min at 30 °C. Kinase assay reactions were terminated by adding
SDS sample buffer, followed by boiling for 5 min. After SDS-PAGE and
electro-transfer, PVDF membranes were Western-blotted with anti-
phospho-GSK-3α/β (Ser21/9) rabbit monoclonal antibody (Akt
Kinase Assay Kit), polyclonal mouse anti-Hsp90 [27], polyclonal
rabbit anti-Aha1 [13], anti-Akt1/2/3 (H-136) (Santa Cruz, catalog #sc-
8312), and anti-phospho-Akt (Ser473) (Cell signaling, catalog
#9271S).
2.4. Luciferase renaturation assay
Refolding of ﬁreﬂy luciferase in RRL was carried out as previously
described with minor modiﬁcations [24]. Luciferase (0.5 mg/ml,
Sigma) was dissolved in stability buffer (25 mM Tricine–HCl (pH
7.8), 8 mM MgSO4, 0.1 mM EDTA, 10 mg/ml bovine serum albumin,
10% glycerol, and 1% Triton X-100), and denatured by heating at 40 °C
for 10 min. His-tagged Aha1 was synthesized by TnT in RRL for
30 min at 30 °C. Naïve TnT lysate containing no plasmid was similarly
incubated and used as a control. The refolding reaction was initiated
by the addition of 1 μl denatured luciferase to the TnT lysate. The
luciferase activity present in the TnT lysates was measured at 0 min
and after a 10 min incubation at 30 °C, by the addition of a 2 μl aliquot
of the TnT lysate into 50 μl of assay buffer (25 mM Tricine–HCl (pH
7.8), 8 mM MgSO4, 0.1 mM EDTA, 33 μM DTT, 470 μM D-luciferin,
240 μM coenzyme A, and 0.5 mM ATP) followed by a 10 s integration
time to measure relative light unit (RLU) production using a Lumac
Bioluminometer (3 M). Reactions were carried out in triplicate and
the experiment was repeated at least three times.
2.5. Identiﬁcation of Aha1-interacting proteins by LC–MS/MS and
Western blotting
HeLa cells were transfected with Flag-Aha1 plasmid or empty
vector using Lipofectamine 2000 transfection reagent (Invitrogen,
catalog #11668019) and incubated at 37 °C in a humidiﬁed incubator
with 5% CO2 for 48 h. Cells were dissociated from tissue culture
ﬂasks (Cell Dissociation Solution Non-enzymatic 1×, Sigma, catalog
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lysis buffer containing 50 mM HEPES (pH 7.4), 2% Igepal CA-630, 0.1%
SDS, 150 mM NaCl, 0.75% deoxycholic acid, 1 mM EGTA, 1 mM NaF,
2 mM Na3VO4, PhosSTOP phosphatase inhibitor cocktail (Roche,
Catalog #04906837001), complete mini protease inhibitor cocktail
(Roche, Catalog #04693124001) and 20 mM sodium molybdate.
Cell lysates were then sonicated, shaken at 4 °C for 20 min and
centrifuged at 14,000 rpm for 10 min. The supernatants were mixed
with anti-Flag agarose (Sigma, catalog #A2220) for 2 h at 4 °C. The
anti-Flag resins were then washed three times with P50T containing
20 mMmolybdate and once with P20T containing 20 mMmolybdate,
followed by elution of the immunoadsorbed proteins by boiling in
SDS-sample buffer and separation of the samples by SDS-PAGE on 8%
gels. For Western blot analysis of co-adsorbed proteins and co-
chaperones, gels were transferred to PDVF membranes. For LC–MS/
MS identiﬁcation of co-adsorbed proteins, gels were stained with
colloidal-Coomassie blue G250 and destained, after which protein
bands were excised, and destained by extensive washing with 50%
acetonitrile/50 mM ammonium bicarbonate pH 8, dehydrated with
100% acetonitrile, and dried brieﬂy. Dried acrylamide pieces were
rehydrated with 10 mM tris-2-carboxyethyl-phosphine (TCEP),
50 mM ammonium bicarbonate, and reduced for 1 h at room
temperature. Subsequently, the reducing buffer was replaced with
55 mM iodoacetamide in 50 mM ammonium bicarbonate, and
samples were alkylated for 1 h at room temperature in the dark.
Samples were then rinsed with ammonium bicarbonate, dehydrated
with acetonitrile, and rehydrated/inﬁltrated with trypsin solution
containing 8 μg/ml of trypsin in 50 mM ammonium bicarbonate. After
overnight digestion at 37 °C, the trypsinolytic peptide products were
extracted with 0.5% triﬂuoroacetic acid, and used for subsequent
analysis by mass spectrometry.
Samples were analyzed on a hybrid LTQ-Orbitrap mass spectrom-
eter (Thermo Fisher Scientiﬁc) coupled to a New Objectives PV-550
nanoelectrospray ion source and an Eksigent NanoLC-2D chromatog-
raphy system. Peptides were analyzed by trapping on a 2.5 cm
ProteoPrepII pre-column (New Objective) and analytical separation
on a 75 μm ID fused silica column packed in house with 10-cm of
Magic C18 AQ, terminated with an integral fused silica emitter pulled
in house. Peptides were eluted using a 5–40% acetonitrile/0.1% formic
acid gradient performed over 40 min at a ﬂow rate of 300 nl/min.
During each one-second full-range FT-MS scan (nominal resolu-
tion of 60,000 FWHM, 300 to 2000 m/z), the three most intense ions
were analyzed via MS/MS in the linear ion trap. MS/MS settings used
a trigger threshold of 1000 counts, monoisotopic precursor selection
(MIPS), and rejection of parent ions that had unassigned charge
states, were previously identiﬁed as contaminants on blank gradient
runs, or were previously selected for MS/MS (data dependent
acquisition using a dynamic exclusion for 150% of the observed
chromatographic peak width). Column performance was monitored
using trypsin autolysis fragments (m/z 421.76), and via blank
injections between samples to assay for contamination.
2.6. Data analysis
Centroided ion masses were extracted using the extract_msn.exe
utility from Bioworks 3.3.1 and were used for database searching with
Mascot v2.2.04 (Matrix Science) and X! Tandem v2007.01.01.1
(www.thegpm.org). Searches were conducted in IPI_human_022209
database using the following search parameters: parent ion mass
tolerance 10 ppm; fragment ion tolerance 0.8 Da; one missed tryptic
cleavage; variable modiﬁcations of pyroglutamate cyclization of
N-terminal Gln, oxidation of Met, formylation or acetylation of the
protein N-terminus, and carbamidomethyl cysteine. Peptide and
protein identiﬁcations were validated using Scaffold v2.2.00
(Proteome Software) and the PeptideProphet algorithm [33]. Proba-
bility thresholds were greater than 99.0% probability for proteinidentiﬁcations, based upon at least 2 unique peptides identiﬁed with
80.0% certainty. Proteins that contained similar peptides and could
not be differentiated based on MS/MS analysis alone were grouped to
satisfy the principles of parsimony.
The interaction of Aha1 with its putative binding proteins
identiﬁed by MS analysis was further examined by Western blotting
of immuno-adsorbed samples prepared from HeLa cells transfected
with Flag-tagged Aha1 as described above, after SDS-PAGE and
electrotransfer to PVDF membrane. Each membrane was incubated
with individual primary antibody, anti-Hsp70 (StressMarq, catalog
#SMC-104A/B, mouse monoclonal), anti-DNAJA1 (Thermo, catalog
#MS-225, HDJ-2 mouse monoclonal), anti-RACK1 (Santa Cruz,
catalog #sc-17754), anti-PPM1G (Abcam, catalog #ab70794), anti-
IQGAP1 (Santa Cruz, catalog #sc-10792), anti-Topoisomerase II alpha
(Abcam, catalog #ab45175), anti-SRPK1 (BD Biosciences, catalog
#611072), anti-DNA-PKcs (Abcam, catalog #ab1832), anti-PKN2
(Abcam, catalog #ab32395), and anti-Ku70/Ku80 (Abcam, catalog
#ab53126) with gentle rocking overnight at 4 °C. After incubation
with alkaline phosphatase-conjugated secondary antibody for 2 h at
room temperature, protein binding was detected by NBT (nitro-blue
tetrazolium chloride)/BCIP (5-bromo-4-chloro-3′-indolyphosphate
p-toluidine salt) reaction or ECL detection kit (Tropix CDP Star
Ready-to-Use with Emerald IITM, part #T2216).
3. Results
3.1. Effect of Hsp90 inhibitors on its interaction with Aha1
The binding of Hsp90 to client proteins and its interactions with
co-chaperones are modulated by the binding and hydrolysis of ATP,
which drives Hsp90 through its reaction cycle (reviewed in [1–3,34]).
Geldanamycin, molybdate and novobiocin inhibit Hsp90 function by
interrupting Hsp90's progression through its reaction cycle, with each
compound having distinct effects on Hsp90's conformation and its
interactions with client proteins and co-chaperones [1–3,34]. Thus,
we examined the interaction of Aha1 with Hsp90 in the presence or
absence of geldanamycin, molybdate and novobiocin to determine
whether Aha1 preferentially interacted with a speciﬁc conformation
of Hsp90. In addition, since the interaction of client proteins with
Hsp90 also stimulates Hsp90's ATPase activity [35], we wished to
address the question of whether Aha1's interaction with Hsp90 had
the characteristics of a co-chaperone or an Hsp90 client.
His-tagged Aha1 was generated by TnT in RRL and immunoad-
sorbed in the presence or absence of molybdate. In the presence of
buffer containing low salt, a very weak interaction between Aha1 and
Hsp90 was detected by Western blotting, that was markedly
stabilized by the presence of molybdate (Fig. 1A). Since molybdate
characteristically stabilizes Hsp90–client complexes to washes with
buffer containing high salt [36–38], while Hsp90–co-chaperone
interactions are salt labile, we examined the salt stability of Hsp90–
Aha1 complexes (Fig. 1A). The amount of Hsp90 that co-adsorbed
with Aha1 was reduced to undetectable levels upon washing with
buffer containing 0.5 M NaCl (Fig. 1A). Thus, the instability of Hsp90–
Aha1 complexes in the presence of high NaCl concentrations is
consistent with it interacting with Hsp90 as a co-chaperone rather
than a client.
The effect of geldanamycin and novobiocin on Hsp90–Aha1
complex formation was then examined (Fig. 1B and C, respectively).
We have previously shown that pre-incubation of lysate with
geldanamycin blocks the ability of molybdate to alter Hsp90's
conformation and stabilize “late” Hsp90 complexes containing
bound client [36]. Hsp90 was immunoadsorbed from TnT lysate that
was or was not pre-incubated with geldanamycin (Fig. 1B). A weak
interaction between [35S]Aha1 and Hsp90 was detected in the
absence of molybdate. Again, the addition of molybdate stabilizes
the interaction of [35S]Aha1 with Hsp90. However, pre-incubation of
Fig. 1. The effect of Hsp90 inhibitors and salt concentration on the interaction of
Aha1with Hsp90. (A) [35S]-labeled His-tagged Aha1 (+) was synthesized by TnT in
reticulocyte lysate at 30 °C for 30 min followed by the addition (or not) of 15 mM
molybdate (MoO4) at the end of the incubation. The newly-synthesized His-tagged
Aha1 was immunoprecipitated (IP) with anti-His antibody resin. Resins were
subsequently washed with buffer containing low salt (P50T) or high salt (P500T),
and co-adsorbing Hsp90 and [35S]-Aha1 were detected by Western blotting and
autoradiography as described under Section 2.1. Naïve RRL containing no plasmid (−)
was used as the control for non-speciﬁc binding. (B) [35S]-His-tagged Aha1 was
synthesized by TnT in RRL at 30 °C for 30 min following the addition of 15 μg/ml GA
(lane 5, 6) or DMSO (vehicle control, lanes 1, 2, 3, 4). After 20 min of further incubation,
the mixtures were supplemented with 15 mM molybdate (lanes 3, 4, 5, 6) or vehicle
control water (lanes 1, 2) and samples were immunoprecipitated with anti-Hsp90
antibody resin, washed with P50T and analyzed for co-adsorbed Aha1 by SDS-PAGE
and autoradiography. (C) [35S]-His-tagged Aha1 was synthesized in TnT reaction for
30 min followed by the addition of 15 mM molybdate (lanes 3, 4, 7, 8) and/or 5 mM
novobiocin (lanes 5, 6, 7, 8). After an additional 20 min of incubation, the samples were
immunoprecipitated with anti-His antibody resin, washed with P50T and analyzed for
co-adsorbed Hsp90 by Western blotting, as described under Section 2.1. NI: control
non-immune IgG.
Fig. 2. Interaction of Aha1 with Hsp90 co-chaperones in RRL and Hela cell extracts.
[35S]-His-tagged Aha1 was translated in TnT reactions at 30 °C for 30 min. Components
of the Hsp90 machine were immunoprecipitated (IP) with (A) anti-Hsp90, anti-p23,
anti-Cdc37, or anti-Hsp70, and (B) anti-FKBP52, anti-HIP, or anti-HOP resin in the
presence of 15 mM molybdate. Hsp90 and Cdc37 were detected by Western blotting,
and [35S]-His-tagged Aha1 binding was detected by autoradiography. NI: control non-
immune IgG. (C) Association of Aha1 with Hsp90 co-chaperones in HeLa cells. Flag-
Aha1 was expressed in HeLa cells and immunoprecipitated from cell extracts as
described under Section 2.5. Samples were analyzed by SDS-PAGE and Western
blotting for the presence of co-adsorbing Hsp70, DNAJA1, p23, c-Src, and Cdc37. Lysate:
input. HeLa cells transfected with empty vector were used as the control for no-speciﬁc
binding.
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reduced Aha1 binding to levels near that observed with no additions
(Fig. 2A). Thus, geldanamycin blocked molybdate's ability to stabilize
the binding of Aha1 to Hsp90.
Novobiocin, on the other hand, has dominant effects to molybdate,
stimulating client release from Hsp90-kinase complexes pre-formed
in the presence of molybdate, and disrupting the interaction between
Hsp90 and co-chaperone components common to “late” chaperone
complexes [26]. Addition of novobiocin, caused a marked reduction in
the molybdate-stabilized interaction of Hsp90 with Aha1 (Fig. 1C),
suggesting that Aha1 did not interact preferentially with novobiocin-
bound Hsp90. Overall, the data suggest that Aha1 preferentially
interacts with the molybdate-bound conformation of Hsp90.
3.2. Presence of other Hsp90 co-chaperone partners in Hsp90–Aha1
complexes
Several reports have examined the interaction of Aha1 with Hsp90
and a number of its co-chaperone partners in vitro using puriﬁedrecombinant proteins [5,8,12]. While the reports agree that Aha1 can
be present in Hsp90 complexes containing Cyp40, contradictory
results were reported on whether Aha1 could associate with Hsp90
complexes containing bound HOP/Sti1p, Cdc37 or p23/Sba1 [5,8,12].
However, the reports did agree that Aha1 directly associated with
Hsp90, as Aha1 did not interact directly with any of Hsp90's other co-
chaperone partners [5,8,12].
Thus, we examined the ability of antibodies directed against Hsp90,
Hsp70, Hip, p60/Hop, Cdc37, FKBP52 and p23 to co-immunoadsorb
[35S]-His-tagged Aha1 to determine the Hsp90/co-chaperone com-
plexes with which Aha1 interacted in the RRL system (Fig. 2A and B).
Aha1 was speciﬁcally co-adsorbed with Hsp90, FKBP52 and p23. No
Aha1 was co-immunoadsorbed with the Hsp90 co-chaperones Cdc37,
Hip or HOP above the level present in the controls for non-speciﬁc
binding. Immunoadsorption of Hsp70 pulled down an amount of [35S]
Aha1 that was slightly above background (Fig. 2A). However, the
results with the anti-Hsp70, Hip, and Cdc37 pull downs were
somewhat equivocal, as signiﬁcantly less Hsp90 was co-adsorbed
compared to the anti-Hsp90, -FKBP52, -p23 and -HOP pull downs.
Subsequently, the interaction of Aha1 with Hsp90 and its co-
chaperones was investigated in HeLa cells that were transfected to
over-express Flag-tagged Aha1. Hsp90 (not shown) and p23 were
detected to co-adsorb with Aha1 from lysates of HeLa cells by Western
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while FKBP52 was detected just above background (not shown). In
addition, Hsc/Hsp70 and its co-chaperoneDNAJA1were observed to co-
adsorb with Aha1 from HeLa cell extracts (Fig. 2C). However, no
detectable HOP (not shown) or Cdc37 was co-adsorbed with Aha1.
Furthermore, the putative Hsp90/Aha1 client kinase c-Src did not co-
adsorb with Aha1. These results indicate that Aha1 interacts with
Hsp90, p23, Hsp70 and DNAJA1 in cells, and that this interaction
appears to occur exclusive of the binding of Cdc37 and HOP.
3.3. Interaction of Aha1 with Hsp90–client complexes
3.3.1. Interaction of Aha1 with v-Src
Aha1 enhances v-Src activity in yeast strains deﬁcient in Hsp90
activity, while v-Src activity is suppressed in yeast strains carrying
deletions of the HCH1 and AHA1 genes [4,5,11], suggesting that the
Src kinase is a possible client protein of Hsp90/Aha1. However, no
direct interaction of Aha1 with Hsp90/v-Src complexes has been
reported. Furthermore, our results, in agreement with work of others
[12], suggest that the binding of Cdc37, the “kinase-speciﬁc” co-Fig. 3. Aha1 does not associate with Hsp90 chaperone complexes containing bound v-Src o
over-expressing HeLa cells (C). (A) [35S]His-tagged Aha1 and [35S]v-Src were synthesized s
20 min with 20 mM molybdate added for the last 5 min. The samples were subjected to
washed once with P100T followed by three washes with P50T and analyzed for co-adsorbi
control for non-speciﬁc binding of Aha1 and TnT reaction containing empty vector (−) was
TnT in RRL with (+) or without (−) 15 μg/ml geldanamycin (GA) at 30 °C for 30 min. Lys
synthesized as described, followed by an additional 30 min incubation at 30 °C. Control sam
adsorbed with anti-Src antibody. Samples were then washed and the tyrosine kinase activity
enolase as described under Section 2.2. Samples were then analyzed by SDS-PAGE follow
Aha1(Lower Panel), or Western blotting with anti-phosphotyrosine antibody to measure v-S
anti-Aha1 (Lower Panel) to examine the co-adsorption of these proteins with v-Src. Input:
the total phosphotyrosine level in HeLa cells. Cultured HeLa cells were transfected with a p
2000 transfection reagent. After 48-hour incubation at 37 °C, cells were lysed by RIPA lysis b
of SDS-sample buffer. Samples were then boiled for 5 min, followed by analysis of the samp
were detected by blotting with rabbit polyclonal anti-Aha1 antibody and the phosphoty
phosphotyrosine monoclonal antibody mixture (Cell Signaling, P-Tyo-100, Cat #9411; andchaperone, and Aha1 to Hsp90 appears to be mutually exclusive.
Therefore, we examined whether Aha1 interacted with molybdate-
stabilized complexes formed between Hsp90, Cdc37 and v-Src in RRL.
Immunoadsorption of Cdc37 speciﬁcally pulled down Hsp90 and v-
Src, but not Aha1, while immunoadsorption of His-tagged Aha1
pulled down Hsp90, but did not co-adsorb any v-Src above the levels
that non-speciﬁcally bound to control resins (Fig. 3A). Thus, there
does not appear to be any direct interaction of Aha1 with Hsp90
complexes containing newly synthesized v-Src in RRL: a ﬁnding that
is consistent with the observation that no c-Scr was detected to be
bound to Aha1 immunoadsorbed from extracts of HeLa cells over-
expressing Flag-tagged Aha1 (Fig. 2C).
The effect of Aha1 overexpression on v-Src activity was also
examined. In the absence of geldanamycin, v-Src matures in RRL
yielding an autophosphorylated v-Src band with a slightly slower
electrophoretic mobility (Fig. 3B, Upper Panel, lane 2). Maturation of
v-Src in RRL containing over-expressed Aha1 did not increase the
amount of autophosphorylated v-Src (Fig. 3B, Upper Panel, lane 3).
Geldanamycin blocked the maturation of v-Src into an active kinase,
whether or not Aha1 was over-expressed (Fig. 3B, Upper Panel, lanesr stimulate v-Src activity (A,B), and phosphotyrosine levels are not increased in Aha1
eparately by TnT in RRL. The reactions were then combined and incubated for another
immunoprecipitation with anti-Cdc37 or anti-His-tag resins. The immunoresins were
ng protein by SDS-PAGE and autoradiography. Non-immune (NI) mouse IgG resin was
the control for non-speciﬁc binding of v-Src. (B) [35S]-Labeled v-Src was synthesized by
ate containing radiolabeled v-Src (+) was mixed with RRL containing [35S]Aha1 (+)
ples were mixed with RRL lacking vector encoding v-Src (−) or Aha1 (−). v-Src was
of immunoadsorbed v-Src was measured by its ability to phosphorylate acid-denatured
ed by autoradiography to examine the interaction between v-Src (Upper Panel) and
rc autophosphorylation (Upper Panel) and tyrosine kinase activity, and anti-Hsp90 and
samples prior to immunoadsorption of v-Src. (C) Over-expression of Aha1 did not alter
cDNA3.1 vector expressing Flag-Aha1 or empty pcDNA3.1 vector using Lipofectamine
uffer containing protease and phosphatase inhibitor cocktails, followed by the addition
les by 8% SDS-PAGE and Western blotting. The endogenous and exogenous Aha1 levels
rosine levels in whole cell lysates were detected by the Western blot with an anti-
P-Tyo-102, Cat #9416; 1:1 mixture).
1097L. Sun et al. / Biochimica et Biophysica Acta 1823 (2012) 1092–11014 and 5). Western blotting with anti-phosphotyrosine antibody,
conﬁrmed that v-Src's electrophoretic mobility shift was due to its
autophosphorylation, and indicated that over-expression of Aha1 did
not stimulate v-Src's autophosphorylation activity (Fig. 3B, anti-
(P-tyr)v-Src). In addition, overexpression of Aha1 did not stimulate
v-Src's tyrosine kinase activity as measured by the ability of
immunoadsorbed v-Src to phosphorylate acid-denatured enolase in
vitro (Fig. 3B, anti-(P-try)enolse). As expected, geldanamycin blocked
the interaction of Hsp90 with v-Src (Fig. 3B, anti-Hsp90) and v-Src
autophosphorylation (Fig. 3B, Upper two panels). The no plasmid
control, and maturation of v-Src in the presence of geldanamycin
conﬁrmed that the phosphotyrosine bands detected by Western
blotting were speciﬁc to the presence of active v-Src (Fig. 3B). Again,
no Aha1 was detected co-immunoadsorbing with v-Src (Fig. 3B,
Lower panel). Thus, a direct assay of v-Src tyrosine activity in lysate
containing elevated levels of Aha1 (~3 times greater than levels of
endogenous Aha1) indicated that Aha1 had no effect on v-Src's
activity.
3.3.2. Interaction of Aha1 with the progesterone receptor
Similarly, we tested the hypothesis that the reported ability of
Aha1 to stimulate SHR function was a result of its direct interaction
with Hsp90/PR complexes. Immunoadsorption of Hsp90 from lysate
expressing [35S]PR and His-tagged [35S]Aha1 coadsorbed both PR and
Aha1, and geldanamycin was found to decrease the association of
both of these proteins with Hsp90 (Fig. 4A). However, analysis of
anti-His-tag pull downs of Aha1 indicated that no [35S]PR was present
in Hsp90/Aha1 complexes stabilized with molybdate in RRL (Fig. 4B).
Thus, similar to the results obtained with v-Src, Aha1 was absent from
complexes formed between Hsp90 and PR, a member of another
major family of Hsp90-dependent clients.
3.3.3. Interaction of Aha1 with Akt
The co-adsorption of Aha1 with the Hsp90 client Akt has been
reported from lysates of cultured HeLa cells [4,5]. To investigate this
reported interaction, HeLa cells were transfected with Flag-tagged
Aha1, lysed and immunoadsorbed with anti-Flag antibody. Western
blotting indicated that Akt was speciﬁcally co-adsorbed with Aha1
(Fig. 5A). To determine the effect of Aha1 on Akt activity, Flag-tagged
Aha1 or empty vector was transfected into HeLa cells. Akt was
immunoadsorbed with anti-Akt/pS473 antibody and its ability to
phosphorylate glycogen synthetase kinase 3 (GSK3) was assayed.
While Western blot analysis with anti-Akt antibody indicated
that equivalent amounts of Akt were present in the cell lysates,
Western blotting with anti-Akt/pS473 indicated that Akt from Aha1
over-expressing cells had a decreased level of this activating
phosphorylation (Fig. 5B, lysate). Consistent with this observation,
the phospho-Akt immunoadsorbed from Aha1 over-expressing cellsFig. 4. Aha1 does not interact with Hsp90 complexes containing the progesterone receptor. [
(GA) at 30 °C for 30 min. To examine steroid hormone receptor binding activity of Aha1, ly
synthesized as described above, followed by an additional 30 min incubation at 30 °C. Cont
(A) or His-tagged Aha1 (B) was adsorbed with anti-Hsp90 or anti-His-tagged antibody in th
followed by Western blotting and autoradiography as described under Section 2.1. NI—Nonhad a decreased ability to phosphorylate GSK3 (Fig. 5B: IP). Thus, in
contrast to the previous report [21], we found that over-expression
of Aha1 decreased rather than increased the activity of Akt in HeLa
cells.
Since, neither v-Src expressed in RRL, nor HeLa cell c-Src could be
detected to interact with Aha1, we also examined whether Aha1 was
present in Hsp90 complexes formed with nascent Akt synthesized in
RRL [39]. Both Hsp90 and Cdc37 were observed to co-adsorb with
nascent His-tagged Akt (Fig. 5C). While binding of Hsp90 to newly
synthesized Akt was maintained in the presence of geldanamycin,
albeit at a reduced level, geldanamycin completely blocked the
binding of Cdc37 to Akt. When the Akt was matured in RRL for a
further 1.5 h, its interaction with Hsp90 and Cdc37 was decreased
(Fig. 5C versus 5D). However, under conditions where addition of
20 mM sodium molybdate stabilized the binding of Hsp90 and Cdc37
with Akt (Fig. 5D), Western blotting with anti-Aha1 antibody did not
detect any Aha1 associated with Akt. Thus, similar to results obtained
with nascent v-Src, Aha1 does not appear to bind to complexes
formed between Hsp90 and nascent Akt in RRL.
3.4. Effect of Aha1 overexpression on client protein activity
Because overexpression of Aha1 stimulated the activity of v-Src
and SHR in yeast strains deﬁcient in Hsp90 function [4,5,12], it has
been generally assumed that stimulation of Hsp90's ATPase activity
would increase its ability to chaperone client folding, and thus,
enhance client protein activity. To test this hypothesis, we examined
the effect that over-expression of Aha1 had on total cellular tyrosine
kinase activity by determining overall phosphotyrosine levels in HeLa
cells by Western blotting. Expression of Aha1 at a level approximately
5-times higher than that of its endogenous expression, caused no
change in the level of tyrosine phosphorylation in HeLa cells (Fig. 3C).
Thus, marked overexpression of Aha1 had no effect on the overall
tyrosine kinase activity in cultured HeLa cells.
To further test this hypothesis, we examined the effect of over-
expression of Aha1 on Hsp90-dependent refolding of thermally
denatured luciferase in RRL [24]. TnT-RRL was incubated in the
presence and absence of plasmid encoding Aha1, and the ability of the
lysates to refold denatured luciferase was measured after 30 min.
Western blotting with anti-Aha1 antibody indicated that there was
approximately a 3-fold higher level of Aha1 in the RRL programmed
with Aha1 plasmid than in the control (not shown). Contrary to
expectations this increase in the expression of Aha1 resulted in a
statistically signiﬁcant ~40% decrease in the rate of luciferase
refolding compared to the control (Fig. 6). Similar results were
obtained upon titration of puriﬁed recombinant Aha1 into RRL (not
shown). Thus, increasing Aha1 levels does not seem to generally
enhance Hsp90's “chaperone activity”.35S]-Labeled PR was synthesized by TnT in RRL with or without 15 μg/ml geldanamycin
sates containing radiolabeled PR (+) were mixed with RRL containing [35S]Aha1 (+)
rol samples were mixed with RRL lacking vector encoding PR (−) or Aha1 (−). Hsp90
e presence of 20 mM molybdate and samples were washed and analyzed by SDS-PAGE
immune IgG control for non-speciﬁc binding.
Fig. 5. Interaction of Aha1 with AKT in HeLa (A,B) cells and RRL (C,D). (A) Empty control vector (wt) or vector for the expression of Flag-tagged Aha1 was transfected into HeLa cells
and cell extracts were immunoadsorbed with anti-Flag agarose. Co-immunoprecipitated AKT was detected by Western blotting. (B) Active AKT was immunoprecipitated from
lysates of control or Aha1 over-expressing HeLa cells and assayed in vitro for kinase activity using GSK-3 fusion protein as the substrate of AKT as described under Section 2.3.
Coadsorbing Hsp90 and Aha1 and the level of phospho-AKT, total AKT and Aha1in the HeLa cell extracts were detected by Western blotting. AKT catalyzed phosphorylation of GSK3
was detected by Western blotting. (C,D) Aha1 does not interact with newly synthesized AKT in RRL. (C) To assess the interaction of endogenous Aha1 with Akt, [35S]-His-tagged Akt
was generated by TnT in RRL for 20 min at 37 °C, followed by an additional 10 min incubation after the addition of 10 μM GA.. [35S]-Aha1 was immunoadsorbed with anti-His
antibody, and the resin was washed once with P60T, twice with P100T and once with P60T, followed by analysis of the samples by SDS-PAGE, Western blotting and/or
autoradiography. (D) To assess the interaction of endogenous Aha1 with matured Akt, [35S]-His-tagged Akt was generated by TnT for 30 min at 30 °C, followed by the addition of
20 mM sodium molybdate (+) or buffer control (−). After an additional incubation for 1.5 h, [35S]-Aha1was immunoadsorbed with anti-His antibody. Since the interaction of
Hsp90 and its associated components is affected by the salt concentration in the wash buffers, the NaCl concentrations in the wash buffer were reduced by 60 mM to control for the
ionic strength of 20 mM Na2MO4 contained in the wash buffers for the molybdate treated samples. Samples were washed as described above and analyzed by SDS-PAGE, Western
blotting and/or autoradiography. (−) No AKT plasmid.
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Since Aha1 could not be detected to interact with v-Src or the PR,
which studies in yeast suggested were putative clients, we ask the
question, to what proteins in HeLa cells does Aha1 interact? Flag-
Aha1 or empty vector was transfected into HeLa cells, and cell
extracts were prepared after 48 h. Extracts were adsorbed with anti-
Flag agarose, and bound proteins were eluted and separated by SDS-
PAGE. Samples were either analyzed directly by Western blotting or
gel bands were excised, digested with trypsin and analyzed by LC–
MS/MS (Supplementary Fig. S1). While Western blotting conﬁrmed
that SRPK1 [20] was coadsorbed with Aha1 (Fig. 7), an interaction
between GTP cyclohydrolase I and Aha1 [22] was not detected (notFig. 6. Over-expression of Aha1 inhibits Hsp90-dependent luciferase renaturation. RRL
containing newly-synthesized Aha1 or mock plasmid control was incubated with
thermally denatured ﬁreﬂy luciferase at 30 °C for 10 min. The difference in luciferase
activity (light units) assayed before and after a 10 min renaturation is plotted. The
values represent the average of 3 independent experiments with a P-value (t test) of
0.049.shown). LC–MS/MS identiﬁed DNA-activated protein kinase (catalytic
subunit), Topoisomerase IIα, Ku80, Ku70, IQGAP1, RACK1, PKN2
protein kinase (a.k.a., PRK2), and PPM1G (a.k.a., PP2Cγ and protein
phosphatase 1C) as proteins that co-adsorbed with Aha1. The
proteins were absent from the gel lane containing proteins from
anti-Flag immuno-adsorption of extracts from HeLa cells transfected
with empty vector. The speciﬁcity of the interactions of these proteins
with Aha1 was further conﬁrmed by Western blotting (Fig. 7).Fig. 7. Conﬁrmation of Aha1 interacting proteins identiﬁed by LC–MS/MS. HeLa cell
lysates from cells transfected with empty vector or vector encoding Flag-Aha1 were
immunoadsorbed with anti-Flag resin and analyzed by SDS-PAGE andWestern blotting
for the presence of the co-adsorbed proteins indicated in the ﬁgure.
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4.1. Co-chaperone components of Hsp90/Aha1 complexes
Aha1 was found to interact with Hsp90 co-chaperone complexes
containing bound Hsp70 and DNAJ1, components of “intermediate”
Hsp90 client complexes, and p23 and FKBP52, which are components
of “late” Hsp90 client complexes (reviewed in [1–3,34]). In addition,
no interaction of Aha1 with Hsp90 complexes containing Cdc37 or
HOP/Sti1 was detected. Recently, it has been reported that Hsp90
forms “mixed” complexes containing components of both intermedi-
ate and late complexes, during Hsp90's transition between these two
states [40]. The ability of molybdate to stabilize Aha1's interaction
with Hsp90 suggests that Aha1 prefers to interact with the
conformation that Hsp90 assumes upon formation of late complexes.
Thus, the data suggest that either a mixture of early (Hsp90/Hsp70/
DNAJ1) and late (Hsp90/FKBP52/p23) Hsp90 complexes containing
Aha1 was pulled down, or that Aha1 is capable of binding to mixed
Hsp90 complexes that are formed during its transition between these
two states.
With respect to p23/Sba1 binding, structural studies suggest that
the binding sites for p23 and Aha1 on Hsp90 overlap [7,41]. However,
p23 has been reported to bind at a stoichiometry of one molecule of
p23 per Hsp90 dimer [8,42]. In addition, the detection of an Hsp90–
Aha1–p23 ternary complex is consistent with a recent report that the
binding of one Aha1 molecule per Hsp90 dimer is sufﬁcient to fully
activate Hsp90's ATPase activity by spanning the two subunits [10].
Thus, p23 and Aha1 could coexist in the same chaperone complex by
binding to opposite faces on the Hsp90 dimer. Still it should be noted
that there is some controversy on whether p23/Sba1 binds to Hsp90
at a ratio of one or two molecule(s) per Hsp90 dimer [8,41,43,44],
with one report noting that the stoichiometry of p23/Sba1 bound per
Hsp90 dimer obtained was dependent upon the ratio of p23 to Hsp90
utilized in the experiment [45].
These results are both in agreement and at odds with previous
reports published in regard to the co-chaperones with which Aha1
can coexist in Hsp90/co-chaperone complexes. While there is
agreement that Aha1 can bind to Hsp90 complexes containing
immunophilins (e.g., the cyclophilin 40 homologs Crp6 and Crp7,
[5,12]), there has been disagreement on whether Aha1 can interact
with Hsp90 complexes containing bound HOP/Sti1, Cdc37 or p23/
Sba1 [5,8,12,43]. As discussed by Gaiser et al. [43], the discrepancy
between the results obtained may be due to several causes: 1) the use
of a mixed human Cdc37/yeast Hsp90 system [5,8,12]; 2) the
utilization of truncated HOP/Sti1(cSti1), and Cdc37 (Cp50) Hsp90
binding constructs [8]; or 3) the employment of different experi-
mental techniques [5,8,12,43]. It is also noteworthy that the binding
properties of yeast and human Cdc37 to Hsp90, as well as the
regulation of Cdc37–Hsp90 complexes by nucleotides and other co-
chaperones differ markedly between the yeast and human systems
[43]. Thus, Hsp90/co-chaperone interactions that are mutually
exclusive in human cells may not be mutually exclusive in yeast. It
should also be noted that these previous reports were based on work
done with puriﬁed recombinant proteins in vitro, which may yield
results different from those obtained here using cell extracts.
4.2. Effect of Aha1 on Hsp90–client protein activity
The observation that over-expression of Aha1 in HeLa decreased
the level of activation of Akt, while increased expression of Aha1 in
RRL inhibited rather than stimulated Hsp90-dependent refolding of
denatured luciferase, indicates that stimulating Hsp90's ATPase
activity may not in general stimulate Hsp90's ability to facilitate
protein folding or activation. This observation is consistent with a
model recently proposed for the role of Aha1 in the Hsp90-dependent
maturation of wild type and mutant/ΔF505 CFTR [9]. In this model,the interaction of Aha1 with Hsp90/CFTR complexes is postulated to
decrease the dwell time of Hsp90 in CFTR complexes, stimulating the
dissociation of Hsp90 from immature, misfolded wild-type or
mutant/ΔF505 CFTR, and the formation of CFTR/Hsp70/DNAJ com-
plexes, thus inhibiting the translocation of the proteins to the plasma
membrane [9,15,46]. Ultimately, Aha1 stimulated dissociation of
Hsp90 led to the ubiquitination of immature or mutant CFTR and its
degradation though the ERAD pathway or targeting to the lysosome
[9,15,46]. It was proposed that decreased dwell time of Hsp90 in
complexes with clients due to Aha1 stimulated ATP hydrolysis can
interfere with maturation or folding of certain clients, but may
stimulate the maturation of other clients (e.g., v-Src) [9]. Such a role
for Aha1 in modulating Hsp90/client interactions is also consistent
with the observation that Aha1 negatively regulates the activity of the
MAL activator in Saccharomyces by stimulating the dissociation of
Hsp90 from the MAL activator prior to its complete maturation [23].
In addition, over-expression of Aha1 has also been observed to
increase total MC4R levels in cells, but decrease the amount of MC4R
that is translocated to the plasma membrane [18]. Such a mechanism
of action would facilitate the turnover of mutant and/or misfolded
proteins that might otherwise have extended interactions with Hsp90
and interfere with cellular proteostasis [9].
Our results suggest that the stimulatory effect that Aha1 has been
reported to have on the activity of v-Src and SHRs in yeast is likely to
be an effect down-stream of Hsp90-dependent folding and matura-
tion of the newly synthesized proteins. While genetic evidence
indicates that over-expression of Aha1 in Hsp90 deﬁcient yeast
restores the activity of exogenously expressed v-Src and enhances the
activity of ectopically expressed SHR [12], no interaction of Aha1 with
Hsp90 complexes formed with newly synthesized v-Src or PR was
observed in RRL, and no interaction of Aha1 with endogenous c-Src
could be detected in HeLa cells. Furthermore, over-expression of Aha1
in RRL had no stimulatory effect on the kinase activity of v-Src, and
Aha1 overexpression in HeLa cells had no effect on cellular
phosphotyrosine levels. These results suggest that the effects of
Aha1 over-expression on the activity of v-Src and SHRs in yeast are
either indirect or mediated through Aha1's interaction with Hsp90
complexes formed with client proteins after their maturation. These
possibilities would be consistent with the observation that the
interaction of Cdc37 and HOP/Sti1 (co-chaperones that are required
for the maturation of kinases and SHRs) with Hsp90 appears to be
mutually exclusive of Aha1. Still the absence of a detectable
interaction between Aha1 and Hsp90/v-Src or Hsp90/PR complexes
might be due to its role in stimulating the dissociation of Hsp90/client
complexes, and that Aha1's interaction with such complexes may be
so transient that we fail to detect it. However, we note that no
interaction of Aha1 was observed with Hsp90/v-Src or PR complexes
that were stabilized by the addition of molybdate, a condition which
also stabilizes the binding of Aha1 to Hsp90. In addition, another
caveat needs to be acknowledged. Because of distinct differences in:
1) the ATPase activities of yeast and human Hsp90; 2) the
interactions of yeast and human Hsp90 with their co-chaperones;
and 3) the effect of these co-chaperone interactions on Hsp90's
ATPase activity (discussed in [43]), Aha1 may have a direct Hsp90-
dependent effect on v-Src activity in yeast, but this effect on v-Src
activity may not be extrapolatable to human cells.
4.3. Identiﬁcation of Aha1 interacting proteins
Because the results discussed above suggested that Aha1 may not
function as a “generic” co-chaperone associated with the folding and
maturation of Hsp90-dependent nascent polypeptides, studies were
initiated to begin to identify proteins that speciﬁcally interacted with
Aha1 in HeLa cells. SRPK1, DNA-PKcs, Topo IIα, Ku80/Ku70, IQGAP1,
RACK1, PKN2 protein kinase, and PPM1G were identiﬁed as proteins
that interact with Aha1. DNA-PKcs, Topo IIα and Ku80/Ku70 function
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repair and telomere maintenance [47,48]. DNA-PKcs [49] and Topo
IIα [50,51] have previously been demonstrated to be present in
multi-meric complexes with Hsp90, while Ku80/Ku70 is a multi-
functional protein complex that acts as the regulatory subunit of
DNA-PKcs [47,48,52]. SRPK1 [20] and PPM1G [53] phosphorylate and
dephosphorylate factors involved in the assembly and regulation of
the spliceosome, respectively. Stress-induced translocation of SRPK1
into the nucleus is accompanied by the dissociation of Hsp90, and
functions to regulate alternate splicing of transcripts that occurs in
response to stress [20]. IQGAP1 is a scaffold protein that integrates
diverse signaling pathways, including pathways involved in regulat-
ing cell proliferation, cell adhesion, and cytoskeletal rearrangements
and cell motility [54,55]. IQGAP1 interacting proteins include the
Hsp90-dependent protein kinases EGFR, c-Src, B-Raf, Akt, and MEK1
[54–56]. RACK1 (receptor of activated protein kinase C) is another
multi-functional scaffold protein [57], one function of which is to
regulate the O2-independent degradation of HIF1α by competing
with Hsp90 for the binding of HIF1α [58,59]. In addition, RACK1 acts
as a scaffolding protein that functions to modulate CFTR activity
[60–63]. PKN2 is a protein kinase C-related protein kinase that plays
an essential role in regulating entry into mitosis and exit from
cytokinesis [64]. PKN2 has been shown to regulate nuclear translo-
cation of a subset of class IIa histone deacetylases [65], and to interact
with PDK1, a Hsp90-dependent protein kinase that modulates
signaling through Akt [66]. Thus, a common feature of the proteins
that were found to interact with Aha1 is that they are part of or
regulate the assembly of oligomeric complexes that contain compo-
nents that interact with Hsp90.
5. Conclusion
In summary, our data suggest that Aha1 may not be a generic co-
chaperone of Hsp90 that generally functions to modulate the Hsp90-
dependent folding of nascent polypeptide chains. Rather Aha1 may
play a role in protein sorting or quality control at membranes, as
suggested from its role in modulating the turnover of CFTR [9,14,15],
the transport of VSV-G [13], and its interaction with activated Akt
([21] and Fig. 5). In addition, consistent with the observation that
Aha1 expression is stress-inducible [5], our data suggest that Aha1
may function in cellular stress responses, such as regulating proteins
involved in DNA repair, and alternate splicing of mRNAs [20] that are
induced by DNA damage and other environmental stresses [67].
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